

Review of: "RAS mutations that have a major impact on current cancer genomic medicine"

Abdalla Mohamed¹

¹ The University of Aberdeen

Potential competing interests: No potential competing interests to declare.

Overall, the short communication is well written and presented. It highlights an important point that not all RAS family mutations are the same and that there are some cases that could benefit from anti-EGFR therapy despite having RAS mutations.

Minor points:

- 1- In the abstract: "Especially, Kirsten Rat Sarcoma (KRAS) silent variants are of concern to be a serious problem in genomic cancer medicine." this sentence is confusing and needs to be rewritten to become clear.
- 2- What does the authors mean by depression here: "Especially, Kirsten Rat Sarcoma (KRAS) silent variants are of concern to be a serious problem in genomic cancer medicine."?
- 3- Heading of Table1: upper half, second column, should be amino acid at position 60 and amino acid at position 61 to become more clear.